Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

23.12 +0.24 (+1.05%)
Streaming Delayed Price Updated: 3:10 PM EST, Dec 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Nanobiotix S.A. - ADSs

< Previous 1 2 3 4 5 6 Next >
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in Jefferies London Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
From Nanobiotix S.A.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.